drugset / Trial / NCT03135028
Entospletinib (ENTO) as Monotherapy and in Combination With Chemotherapy in Japanese Adults
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary objective of this study is to evaluate the safety and tolerability of entospletinib (ENTO) monotherapy and in combination with chemotherapy in Japanese participants.
Timeline
- Start
- 2017-05-19
- Primary completion
- 2019-02-26
- Completion
- 2019-02-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Entospletinib | Small molecule | 400 mg | Oral |
| Background | Cytarabine | Small molecule | 100 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | 1 g/kg | Intravenous |
| Background | Cytarabine | Small molecule | 3 g/kg | Intravenous |
| Background | Daunorubicin | Small molecule | 60 mg/m2 | Intravenous |